Hot search: Supplier  LED  payment  China  Starr  Light  Chemicals  insurance  gas  software 
 
Home > News > Market > Content

Sagent Has Introduced Irinotecan Injection in Single Dose Vials

increase font size  reduce font Add date: 2016-11-30  Hits:95
Core prompt: Sagent Pharmaceuticals, a specialty pharmaceutical company, has introduced Irinotecan injection in two latex free, preservative free single dose vials. The antineoplas

Sagent Pharmaceuticals, a specialty pharmaceutical company, has introduced Irinotecan injection in two latex free, preservative free single dose vials.

The antineoplastic agent of the topoisomerase I inhibitor class, in combination with 5-fluorouracil and leucovorin, is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

Irinotecan features the company's PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors, the company said.

The Irinotecan has approximately $28m sales in the US market for twelve-months ended March 2012, according to IMS data.

 

 
 
[ NewsSearch ]  [ Send Fav ]  [ Share ]  [ Print ]  [ Send Report ]  [ Close ]

 
Total0bar [View All]  Related Comments

 
Photo Recommended
Recommend News
Click Rank
 
Home | Products | Suppliers | News | Tradeshow | Sitemap | Message | RSS Feed